SBRT doubles 5-year survival in oligometastatic cancers

‘Stereotactic body radiation therapy (SBRT) in patients with oligometastatic disease from prostate, breast, colon and lung cancers is showing very promising results from the data just presented at the 2018 American Society for Radiation Oncology (ASTRO) conference. We eagerly await the publication of these results to further guide our treatment decisions,’ said GenesisCare Radiation Oncologist A/Prof Raphael Chee.

For more information: https://www.hcpfeed.com/2018/10/17/sbrt-doubles-5-year-survival-in-oligometastatic-cancers/

Whether it’s for diagnosis or treatment, patients attending the PCC are treated as individuals by a team of specialist doctors and allied health professionals with complimentary skill sets who really do care. It’s a true multidisciplinary approach.

It’s what makes the PCC different.